MedTrace Logo

Effects of Chronic Use of Doxazosin in Men With Benign Prostatic Hyperplasia

NCT00730418 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2010-08-26

No results posted yet for this study

Summary

In this study, we investigate the changes of the expression of alpha adrenergic receptor in the prostate tissue during 2-yr medication period in the man with benign prostatic hyperplasia. And we also evaluate the efficacy and safety of 24 mo-treatment with doxazosin (4mg, 8mg)

Conditions

  • Benign Prostatic Hyperplasia

Interventions

DRUG

Doxazosin

Treatment with doxazosin 4mg daily for 24 mos

DRUG

Doxazosin

Treatment with doxazosin 8mg daily for 24 mos

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Kru-Sung Lee, Ph.D., M.D. · Samsung Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00730418 on ClinicalTrials.gov